A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Coutant, Frédéric ^a,b   Sanchez David, Raul Yusef ^a   Félix, Tristan ^a   Boulay, Aude ^a,c   Caleechurn, Laxmee ^a,d   Souque, Philippe ^a   Thouvenot, Catherine ^a   Bourgouin, Catherine ^a   Beignon, Anne Sophie ^a   Charneau, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR DE BANGUI   (Central African Republic)

^d Centre de Recherche   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; LENTIVIRUS VECTOR; MALARIA VACCINE; PROTEIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PROVOCATION TEST; SPOROZOITE; VACCINATION; VIRUS PARTICLE;

ANIMALS; EPITOPES; FEMALE; GENETIC VECTORS; HEK293 CELLS; HEPATOCYTES; HUMANS; LENTIVIRUS; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MODELS, GENETIC; PLASMODIUM YOELII; PROTOZOAN PROTEINS; SPOROZOITES;

ANIMALIA; MUS; PLASMODIUM YOELII;

EID: 84868323073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048644     Document Type: Article

References (86)

1. Doolan DL, Dobano C, Baird JK, (2009) Acquired immunity to malaria. Clin Microbiol Rev 22: 13-36.
2. Prudencio M, Rodriguez A, Mota MM, (2006) The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol 4: 849-856.
3. Menard R, Heussler V, Yuda M, Nussenzweig V, (2008) Plasmodium pre-erythrocytic stages: what's new? Trends Parasitol 24: 564-569.
4. Bannister LH, Mitchell GH, (2009) The malaria merozoite, forty years on. Parasitology 136: 1435-1444.
5. Rieckmann KH, (1990) Human immunization with attenuated sporozoites. Bull World Health Organ 68 (Suppl):: 13-16-.
6. Nussenzweig RS, Vanderberg JP, Most H, Orton C, (1969) Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature 222: 488-489.
7. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334: 475-480.
8. Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, et al. (1998) Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A 95: 7648-7653.
9. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, et al. (2011) Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6: e25868.
10. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, et al. (2012) Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7: e31208.
11. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, et al. (2010) A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 107: 6958-6963.
12. Hill AV, (2011) Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 366: 2806-2814.
13. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, et al. (2011) Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 202: 1076-1087.
14. Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, et al. (2011) Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J 10: 222.
15. Gueirard P, Tavares J, Thiberge S, Bernex F, Ishino T, et al. (2010) Development of the malaria parasite in the skin of the mammalian host. Proc Natl Acad Sci U S A 107: 18640-18645.
16. Amino R, Giovannini D, Thiberge S, Gueirard P, Boisson B, et al. (2008) Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe 3: 88-96.
17. Baer K, Klotz C, Kappe SH, Schnieder T, Frevert U, (2007) Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 3: e171.
18. Cockburn IA, Tse SW, Radtke AJ, Srinivasan P, Chen YC, et al. (2011) Dendritic cells and hepatocytes use distinct pathways to process protective antigen from plasmodium in vivo. PLoS Pathog 7: e1001318.
19. Berenzon D, Schwenk RJ, Letellier L, Guebre-Xabier M, Williams J, et al. (2003) Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. J Immunol 171: 2024-2034.
20. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, et al. (2008) Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 105: 14017-14022.
21. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, et al. (2011) CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187: 1347-1357.
22. Nganou-Makamdop K, van Gemert GJ, Arens T, Hermsen CC, Sauerwein RW, (2012) Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLoS One 7: e36508.
23. He Y, Zhang J, Donahue C, Falo LD Jr, (2006) Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24: 643-656.
24. Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, et al. (2006) Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 13: 310-319.
25. Buffa V, Negri DR, Leone P, Borghi M, Bona R, et al. (2006) Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol 19: 690-701.
26. Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, et al. (2007) Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 15: 1203-1210.
27. Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, et al. (2008) Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo. Eur J Immunol 38: 1867-1876.
28. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, et al. (2006) A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 8: 265-274.
29. Chapatte L, Ayyoub M, Morel S, Peitrequin AL, Levy N, et al. (2006) Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res 66: 5461-5468.
30. Beignon AS, Mollier K, Liard C, Coutant F, Munier S, et al. (2009) Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 83: 10963-10974.
31. Adotevi O, Mollier K, Neuveut C, Dosset M, Ravel P, et al. (2010) Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 115: 3025-3032.
32. Pichlmair A, Diebold SS, Gschmeissner S, Takeuchi Y, Ikeda Y, et al. (2007) Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 81: 539-547.
33. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, et al. (2010) HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 84: 5627-5636.
34. Rossetti M, Gregori S, Hauben E, Brown BD, Sergi LS, et al. (2011) HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther 22: 177-188.
35. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, et al. (2003) In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111: 1673-1681.
36. Furmanov K, Elnekave M, Lehmann D, Clausen BE, Kotton DN, et al. (2010) The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors. J Immunol 184: 4889-4897.
37. Goold HD, Escors D, Conlan TJ, Chakraverty R, Bennett CL, (2011) Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors. J Immunol 186: 4565-4572.
38. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
39. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
40. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, et al. (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
41. Di Nunzio F, Felix T, Arhel NJ, Nisole S, Charneau P, et al. (2012) HIV-derived vectors for therapy and vaccination against HIV. Vaccine 30: 2499-2509.
42. Wanisch K, Yanez-Munoz RJ, (2009) Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 17: 1316-1332.
43. Vargas J Jr, Gusella GL, Najfeld V, Klotman ME, Cara A, (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15: 361-372.
44. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, et al. (2006) Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12: 348-353.
45. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, et al. (2006) Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A 103: 17684-17689.
46. Matrai J, Cantore A, Bartholomae CC, Annoni A, Wang W, et al. (2011) Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53: 1696-1707.
47. Coutant F, Frenkiel MP, Despres P, Charneau P, (2008) Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3: e3973.
48. Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, et al. (2007) Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15: 1716-1723.
49. Karwacz K, Mukherjee S, Apolonia L, Blundell MP, Bouma G, et al. (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83: 3094-3103.
50. Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, et al. (2010) Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. J Biomed Biotechnol 2010: 534501.
51. Hu B, Yang H, Dai B, Tai A, Wang P, (2009) Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 20: 1652-1664.
52. Hu B, Dai B, Wang P, (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28: 6675-6683.
53. Grasso F, Negri DR, Mochi S, Rossi A, Cesolini A, et al. (2012) Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Int J Cancer.
54. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A, (2010) From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 6: 90-96.
55. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V, (1980) Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 151: 1504-1513.
56. Rodrigues M, Nussenzweig RS, Zavala F, (1993) The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 80: 1-5.
57. Kumar KA, Sano G, Boscardin S, Nussenzweig RS, Nussenzweig MC, et al. (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444: 937-940.
58. Oliveira GA, Kumar KA, Calvo-Calle JM, Othoro C, Altszuler D, et al. (2008) Class II-restricted protective immunity induced by malaria sporozoites. Infect Immun 76: 1200-1206.
59. Leavitt AD, Robles G, Alesandro N, Varmus HE, (1996) Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol 70: 721-728.
60. Weiss WR, Mellouk S, Houghten RA, Sedegah M, Kumar S, et al. (1990) Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 171: 763-773.
61. Franke ED, Sette A, Sacci J Jr, Southwood S, Corradin G, et al. (2000) A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture. Infect Immun 68: 3403-3411.
62. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS, (2001) Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A 98: 11491-11496.
63. Kumar KA, Baxter P, Tarun AS, Kappe SH, Nussenzweig V, (2009) Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites. PLoS One 4: e4480.
64. Schmidt NW, Butler NS, Badovinac VP, Harty JT, (2010) Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 6: e1000998.
65. Schmidt NW, Butler NS, Harty JT, (2011) Plasmodium-host interactions directly influence the threshold of memory CD8 T cells required for protective immunity. J Immunol 186: 5873-5884.
66. Chakravarty S, Baldeviano GC, Overstreet MG, Zavala F, (2008) Effector CD8+ T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infect Immun 76: 3628-3631.
67. Trimnell A, Takagi A, Gupta M, Richie TL, Kappe SH, et al. (2009) Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol 183: 5870-5878.
68. Butler NS, Schmidt NW, Harty JT, (2010) Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J Immunol 184: 2528-2538.
69. Gruner AC, Mauduit M, Tewari R, Romero JF, Depinay N, et al. (2007) Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PLoS One 2: e1371.
70. Mauduit M, Gruner AC, Tewari R, Depinay N, Kayibanda M, et al. (2009) A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS One 4: e7717.
71. Mauduit M, Tewari R, Depinay N, Kayibanda M, Lallemand E, et al. (2010) Minimal role for the circumsporozoite protein in the induction of sterile immunity by vaccination with live rodent malaria sporozoites. Infect Immun 78: 2182-2188.
72. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, et al. (2003) Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A 100: 9952-9957.
73. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, et al. (2011) Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9: 451-462.
74. Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M, (1998) Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16: 1812-1817.
75. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
76. Baumann JG, Unutmaz D, Miller MD, Breun SK, Grill SM, et al. (2004) Murine T cells potently restrict human immunodeficiency virus infection. J Virol 78: 12537-12547.
77. Hatziioannou T, Martin-Serrano J, Zang T, Bieniasz PD, (2005) Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells. J Virol 79: 15586-15589.
78. Tsurutani N, Yasuda J, Yamamoto N, Choi BI, Kadoki M, et al. (2007) Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells. J Virol 81: 677-688.
79. Tervo HM, Goffinet C, Keppler OT, (2008) Mouse T-cells restrict replication of human immunodeficiency virus at the level of integration. Retrovirology 5: 58.
80. Bobadilla S, Sunseri N, Landau NR (2012) Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Ther.
81. Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, et al. (2010) Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS One 5: e12294.
82. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, et al. (1994) HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 241: 651-662.
83. Ozaki LS, Gwadz RW, Godson GN, (1984) Simple centrifugation method for rapid separation of sporozoites from mosquitoes. J Parasitol 70: 831-833.
84. Chattopadhyay R, Conteh S, Li M, James ER, Epstein JE, et al. (2009) The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine 27: 3675-3680.
85. Grillot D, Michel M, Muller I, Tougne C, Renia L, et al. (1990) Immune responses to defined epitopes of the circumsporozoite protein of the murine malaria parasite, Plasmodium yoelii. Eur J Immunol 20: 1215-1222.
86. Zhu R, Mancini-Bourgine M, Zhang XM, Bayard F, Deng Q, et al. (2011) Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice. J Virol 85: 10201-10212.